Roche to make $1.9bn acquisition
CIPhotos / iStockphoto.com
Bristol-Myers Squibb (BMS) has agreed to pay $1.85 billion for an immuno-oncology programme.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
BMS, immuno-oncology, commercialisation, licence, cancer, biotechnology, Nekta Therapeutics,